Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients
- PMID: 9817621
- DOI: 10.1097/00004850-199809005-00010
Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients
Abstract
The response to antidepressants is not limited by age and there are sufficient data from the clinical trial databases to support the view that antidepressants are effective in both younger and older patients. Depression is common in the elderly although it may frequently be overlooked. Management is complicated by physiological changes associated with ageing and also by the increased likelihood of comorbid physical illness. These factors have to be taken into consideration in selecting antidepressants for the treatment of elderly patients. The older tricyclic antidepressants are associated with well known anticholinergic effects that may be a particular problem for the elderly and can have serious consequences. The development of newer antidepressants has focused on compounds that are more selective in their pharmacological effects with the aim of reducing the unwanted effects. The selective serotonin reuptake inhibitors have a more benign side-effect profile and are better tolerated than the older tricyclic antidepressants. There are relatively few studies carried out specifically in an elderly population but the efficacy of selective serotonin reuptake inhibitors has been shown both in specific studies in the elderly and in the analyses of elderly patients included in clinical trials of new antidepressants. Their efficacy and improved safety and tolerability profile recommend them for use in the treatment of depression in elderly patients.
Similar articles
-
Selective serotonin reuptake inhibitors in older patients. A tolerability perspective.Drugs Aging. 1997 Mar;10(3):209-18. doi: 10.2165/00002512-199710030-00005. Drugs Aging. 1997. PMID: 9108894 Review.
-
[Pharmacotherapy of depression in the elderly].Nervenarzt. 2000 Jan;71(1):1-8. doi: 10.1007/s001150050001. Nervenarzt. 2000. PMID: 10695026 Review. German.
-
[Selective serotonin reuptake inhibitors and newer antidepressive substances in child and adolescent psychiatry].Z Kinder Jugendpsychiatr Psychother. 2002 Aug;30(3):173-83. doi: 10.1024//1422-4917.30.3.173. Z Kinder Jugendpsychiatr Psychother. 2002. PMID: 12227220 Review. German.
-
WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).Cochrane Database Syst Rev. 2007 Jul 18;(3):CD002791. doi: 10.1002/14651858.CD002791.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636706 Review.
-
Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.Cochrane Database Syst Rev. 2000;(4):CD002791. doi: 10.1002/14651858.CD002791. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD002791. doi: 10.1002/14651858.CD002791.pub2 PMID: 11034764 Updated. Review.
Cited by
-
Chronic depression in the elderly: approaches for prevention.Drugs Aging. 2001;18(7):507-14. doi: 10.2165/00002512-200118070-00004. Drugs Aging. 2001. PMID: 11482744 Review.
-
β-Arrestin 2 mediates the anti-inflammatory effects of fluoxetine in lipopolysaccharide-stimulated microglial cells.J Neuroimmune Pharmacol. 2014 Sep;9(4):582-90. doi: 10.1007/s11481-014-9556-y. Epub 2014 Jul 18. J Neuroimmune Pharmacol. 2014. PMID: 25035139
-
Suicide in our elders : A 10-year review of kentucky medical examiner cases.Forensic Sci Med Pathol. 2006 Dec;2(4):253-62. doi: 10.1385/FSMP:2:4:253. Forensic Sci Med Pathol. 2006. PMID: 25868771
-
Fluoxetine Inhibits NLRP3 Inflammasome Activation: Implication in Depression.Int J Neuropsychopharmacol. 2016 Sep 21;19(9):pyw037. doi: 10.1093/ijnp/pyw037. Print 2016 Sep. Int J Neuropsychopharmacol. 2016. PMID: 27207922 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical